BioCryst Pharma (BCRX) PT Raised to $21 at Piper Sandler, 'we continue to recommend shares'
Tweet Send to a Friend
Piper Sandler analyst Tyler Van Buren raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $21.00 (from $20.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
